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Abstract: The human microbiome consist of the composite genome of native flora that 
have evolved with humanity over millennia and which contains 150-fold more genes than 
the human genome. A “healthy” microbiome plays an important role in the maintenance of 
health and prevention of illness, inclusive of autoimmune disease such as inflammatory 
bowel disease (IBD). IBD is a prevalent spectrum of disorders, most notably defined by 
Crohn’s disease (CD) and ulcerative colitis (UC), which are associated with considerable 
suffering, morbidity, and cost. This review presents an outline of the loss of a normal 
microbiome as an etiology of immune dysregulation and IBD pathogenesis initiation. We, 
furthermore, summarize the knowledge on the role of a healthy microbiome in terms of its 
diversity and important functional elements and, lastly, conclude with some of the 
therapeutic interventions and modalities that are now being explored as potential 
applications of microbiome-host interactions. 
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1. Introduction 
The human microbiome is the collective genome of indigenous microbiologic flora that has evolved 
with mankind over millennia. From the moment of birth, each part of the body becomes colonized by 
characteristic populations of organisms belonging to each of the three domains of life, Archaea, 
Bacteria and Eukarya [1,2]. However, the human gut microbiome is particularly distinct in that it is 
home to a plethora of bacteria, an estimated 100 trillion cells, which is approximately 10-fold more 
than the total number of human cells [3] and which encodes for 150-fold more unique genes than our 
own genome [4]. The majority of these bacteria cannot easily be cultivated using traditional culture 
techniques, and it has only been since the application of sequencing technology that the complement of 
human flora has been described in greater complexity [5]. Our species has co-evolved with these 
micro-organisms in a mutualistic fashion, and we have come to rely on them for many processes 
including immune system maturation, nutrition, maintenance of intestinal barrier permeability and 
function, and prevention of infection with pathologic species [3]. Indeed, the gut microbiota reside in 
close proximity to the luminal surface of the large and small bowel, placing them in near proximity to 
the immune system, and endowing them with a key role in immune function and maturation [6]. It has 
become increasingly clear that this fragile balance of organisms has many important associations with 
regards to the maintenance of health and the prevention of illness. It was our aim to review some of 
these concepts with a special emphasis on the role of the intestinal microbiota in inflammatory bowel 
disease (IBD). 
It has been suggested that individuals can be categorized into three distinct enterotypes that are 
separated by dominance in the proportions of one of three genera: Bacteroides (enterotype 1), 
Prevotella (enterotype 2), and Ruminococcus (enterotype 3) [7]. These clusterings appear to have 
developed in response to primarily dietary environmental factors [7]. In this original study, the authors 
concluded that the robustness of these enterotypes across populations, as well as across phylogenetic 
and functional levels, was indicative of the fact that they appear to be the result of a limited number of 
well-balanced discrete bacterial community compositions [7]. However, more recent studies have 
demonstrated the existence of abundance gradients rather than distinct clustering, and have shown that 
the type of methodology used to examine microbiome composition can have significant effects on 
conclusions drawn [8]. 
2. Microbiome Alterations and Inflammatory Bowel Disease Immune Dysregulation 
Inflammatory bowel disease is a chronic inflammatory disorder of the intestinal tract that is 
associated with abdominal pain, intestinal bleeding, weight loss, and diarrhea. The two most common 
forms of the condition include Crohn’s disease (CD) and ulcerative colitis (UC) [9]. These diseases are 
associated with considerable morbidity, and place a significant burden on individuals, families, and 
society, accounting for an estimated $1.8 billion of expense per year in Canada alone [10,11]. The 
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cause of IBD remains unknown; however, it is thought to occur in genetically-predisposed individuals 
who are exposed to microbial, dietary, and environmental triggers [12]. The incidence of IBD has 
increased dramatically in developed countries over the past 50 years and has been linked with 
modernization and Western lifestyles [11]. Environmental risk factors are an essential component in 
the pathogenesis of IBD and are believed to be largely responsible for the rapid increase in world-wide 
incidence [12]. Please refer to Box 1. 
Box 1. Factors affecting the microbiome. 
• Age 
• Genetics 
• Diet 
• Medications (antibiotics, etc.) 
• Smoking status 
• Obesity 
• Pregnancy-status 
In infants, gut microbial communities undergo radical compositional and functional changes in 
response to environmental exposures until a relatively stable community becomes established by 
approximately 2–3 years of age [13]. Establishment of the gut microbiome is influenced by early diet, 
antibiotic exposure, and method of birth, breast milk composition, and genetic background [14–17]. 
Antibiotic use during this period can significantly alter the composition of the gut microbiota and 
result in long term decreases in diversity and altered trajectories of immune development, which can 
modulate susceptibility to disease in later life [13,18,19]. Indeed, antibiotic exposure and infections 
during the first year of life have been identified as independent risk factors for IBD [20–22]. This is 
due to the fact that gut microbiota play an important role in immune regulation and barrier function of 
the gut, and that consequent alteration thereof may result in the loss of tissue integrity [23]. Both the 
innate and adaptive arms of the immune system have been shown to play a role in IBD, with altered 
adaptive immune function being the primary contributor to disease pathogenesis [6]. In general, this 
occurs mainly through increased pro-inflammatory cytokines driven by the T-helper subsets or by lack 
of effective anti-inflammatory regulatory T-cells [6]. 
Changes in innate immunity are also important and evidence exists that alterations in innate 
immune function are the primary driver of dysfunctional adaptive immune responses. It has been 
demonstrated that intestinal epithelial cells may directly or indirectly recognize luminal  
micro-organisms, and that toll-like receptors (TLRs) may be essential in the maintenance of epithelial 
cell homeostasis [24]. TLRs are specialized trans-membrane receptors of the interleukin-1 superfamily, 
which recognize and respond to pathogen-associated molecular patterns (PAMPS). The interactions 
between such TLRs and their ligands are involved in the clearance of pathogenic bacteria, leukocyte 
recruitment, epithelial homeostasis, and maintenance of barrier immunity. Many TLRs are upregulated 
in IBD once inflammation is established due to the increased presence of TLR promoter inducers, 
including inflammatory cytokines and NF-КB [24]. A loss of TLR signaling homeostasis in either 
direction, either an increase or decrease in activity, is thought to play a potential role in IBD 
pathogenesis [25]. 
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Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), also known as caspase 
recruitment domain-containing protein 15 (CARD15), is a protein which plays an important role in 
immune system functioning via recognition of bacterial molecules (such as peptidoglycans) and 
stimulation of appropriate responses. NOD2 alleles are mutated in approximately 15% of CD patients, 
and this can result in defective neutrophil recruitment in these patients as a result of NOD2 and 
interleukin 8 (IL-8), and NOD2 and TLR receptor pathway interactions [26]. This supports the concept 
that the adaptive immune dysfunction in CD may occur due to a failure to receive an early priming 
signal to pathogenic micro-organisms, resulting in a failure to clear them and the development of 
abnormal subsequent immune responses to their antigens. Studies now suggest that CD patients with 
abnormal NOD2 have an increased susceptibility to the generation of strongly polarised Th1 
responses, resulting in an overly aggressive adaptive immune response to common intestinal flora and 
thereby setting the stage for IBD [27]. 
The general concept of immune dysregulation has led credence to the “hygiene hypothesis”, a 
theory that has been advanced as a possible explanation for the increased incidence of IBD, which 
claims that improvements in hygiene—particularly in developed countries—are congruent with a rise 
in autoimmune illnesses [9,11]. Strachan (1989) was the first scientist to connect this hypothesis to an 
increase in allergic diseases and believed that a child could be overly protected from exposure to 
microbes with lack of exposure to these agents, in early childhood, resulting in more widespread 
clinical expression of atopy [28] due to immune aberrancy. It is for this reason that many scientists 
now advocate for a moderate approach towards cleanliness in young children [29]. 
3. Microbiome Bacterial Dysbiosis in IBD Pathogenesis 
A growing body of literature implicates the abnormal overgrowth or dominance of particular 
bacterial species, at the expense of others, in the pathogenesis of IBD. Notably, mouse model studies 
of IBD have shown protection against the development of IBD in a germ-free environment, and lend 
credence to the role of gut flora in the pathogenesis of this spectrum of illnesses [30]. Furthermore, 
other studies have revealed that the intestinal flora of patients with IBD have less bacterial species 
diversity and less stability over time, suggestive of an association between alteration of the human 
microbiota and development of this type of disease [31]. In healthy hosts, Firmicutes, felt to contribute 
in a key fashion to micronutrient metabolism, are amongst the most dominant constituents of the 
human indigenous gut microflora, accounting for the largest proportion (75%) of bacteria [2]. Several 
studies to date [32–34] have demonstrated reduced Firmicutes, in particular Faecalibacterium 
prausnitzii and Roseburia, and increased Ruminococcus and Enterobacteriaceae, especially adherent 
invasive Escherichia coli (AIEC), in IBD [35–45]. 
Some research to date has demonstrated an increased prevalence of Escherichia coli in the ileum of 
CD patients [36], and a very recent study has shown the ability of E. coli to trigger and potentiate 
intestinal inflammation in mouse models [46]. Despite, the association of this particular organism with 
IBD and, in particular, CD, the precise role of adherent-invasive E. coli (AIEC) in the initiation or 
activation of IBD is not yet fully defined. However, there is evidence for upregulation of microRNAs, 
which reduce expression of proteins necessary for the autophagy response in intestinal cells [47]. This 
suggests that such infected epithelial cells are prevented from self-degradement and recycling of cell 
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components. One theory is that AIEC strains, having the capability of adhering to and invading both 
intestinal epithelial cells and macrophages, can translocate across the bowel wall and continuously 
activate further macrophages, leading to the formulation of granulomas [36]. It is known that  
micro-organisms that are able to penetrate the bowel epithelial barrier and to bypass macrophage 
killing can trigger a powerful and long lasting inflammatory response [48,49]. 
Other research has reported an interesting increased prevalence of other organisms, including 
Mycobacterium avium subspecies paratuberculosis (MAP) in the intestinal tissue of CD patients [50,51]. 
MAP has been defined as the etiology of Johne’s disease in cattle, a chronic granulomatous illness that 
is clinically and pathologically similar to CD in humans [52]. Moreover, several studies have revealed 
that a high proportion of CD patients are infected with MAP compared to persons not having IBD [53]. 
In fact, a fairly recent imputation-based association analysis was quite conclusive in the overlap and 
correlation shown between susceptibility loci for CD and infection with MAP [54]. Unfortunately, 
however, no research to date has either confirmed or denied the precise role of any particular 
organisms in IBD. In fact, the source of MAP in humans is felt by some researchers to be either an 
environmental or zoonotic epiphenomenon. A two-year study by Selby et al. revealed that empiric 
therapy typically effective against MAP, with clarithromycin, rifabutin, and clofazimine for up to two 
years, did not provide sustained benefits [55]. On the other hand, using the data from this study, one 
can also refute the conclusions drawn, noting that the antibiotic arm did significantly better than the 
control arm for as long as antibiotics were administered [56]. This is suggestive that MAP is a 
significant player in at least a subset of IBD patients, and that this type of therapy may be effective for 
them. Further study will be necessary to sort out this controversy. 
An emerging theory is that a dysbiosis or imbalance of intestinal flora may be a trigger for IBD in 
those who may be susceptible, a problem that is normally avoided through the maintenance of a 
healthy microbiome. There are many reasons why the presence of normal healthy commensal 
organisms prevents this process from occurring. One is that commensal microbes resist colonization by 
enteric the pathogens listed above, both directly and indirectly [57]. There are several ways in which 
this is achieved. Firstly, the most basic method in which normal microbiota favour resistance against 
opportunistic infection is via niche competition. This involves competition for sites of colonization and 
nutrient uptake at host epithelial surfaces [58], and modulation of protective immune responses [57]. 
Another modality by which commensal organisms help resist colonization by bacteria associated with 
IBD is by promotion of barrier immunity. An example of this would be induction of epithelial 
production of mucin, secretion of mucosal immunoglobulins and the expression of antimicrobial 
peptides via host TLR recognition of PAMPs [57] as alluded to previously. Yet a third modality of 
pathogen resistance relates to the anaerobic environment of the bowels, a factor which allows 
particular gut commensals to harness energy via fermentation of nutrients passing through the lumen, 
resulting in the production of short chain fatty acids (SCFAs). SCFAs include acetate, butyrate and 
propionate, and are resistant starches that are generally not well digested in the upper GI tract [59]. 
SCFAs strengthen the intestinal epithelium by increasing tight junction protein (TJP) production and 
by increasing transepithelial electrical resistance (TEER) [2] as well as by affecting the immune 
system directly [60]. Thus, it is clear that diet, too, by selecting for particular micro-organisms and by 
resulting in specific metabolites, has a profound impact on the selection of existing normal intestinal flora. 
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4. The Microbiome, Obesity and CD 
The worldwide obesity epidemic has more than doubled since 1980, and this condition is associated 
not solely with metabolic disorders, including type 2 diabetes and cardiovascular disease, but also with 
a wide variety of disorders such as cancer, sleep apnea, osteoarthritis and gallbladder disease [61]. 
Though the present view is that the major etiology of obesity is unbalanced energy intake and 
expenditure in association with genetic predisposition, environmental factors may also play a role. 
Amongst the important outside factors impacting the host’s response to diet is the gut microbiome [62]. 
The initial demonstration of particular alterations in composition between the intestinal flora of obese 
and lean phenotypes was made in leptin-deficient mice, in which the guts of obese mice contained 
fewer Bacterioidetes and increased Firmicutes than other mice [63]. Subsequent studies revealed that 
the transfer of obese mouse gut flora to germ-free mice could reproduce the donor obese phenotype in 
the recipient mice [64], and several recent studies, using pyrosequencing and advanced PCR 
techniques, have demonstrated that high-fat diets increase the Firmicutes/Bacterioidetes ratio and 
decrease Bifidobacterium spp. [65]. Moreover, a higher abundance of Ruminococcaceae and 
Rikenellaceae was seen in leptin-resistant obese and diabetic mice than their slim counterparts [66]. Of 
some interest, it has also been shown that bacterial ATPase complexes correlate strongly with human 
BMI, further supporting the association between the intestinal flora’s capacity for energy harvest and 
obesity in the host [67]. Moreover, adipocytes have been demonstrated to release a variety of 
proinflammatory cytokines and peptides, and it is believed that visceral adiposity may play an 
important role in the commencement and maintenance of inflammation in CD [68]. Based on a  
time-trend analysis from data collected between 1991 and 2008, a clear correlation has been shown 
between increasing weight over time and CD [68]. 
5. Human Gut Microbiome Diversity and Functional Changes 
It has recently been discovered that the evolutionary composition of gut bacterial flora, regardless 
of geography, evolves towards an “adult” phenotype by the third year of life [69]. Furthermore, 
regardless of geography, interpersonal variation in gut flora is greater between children than between 
adults [69]. Moreover, microorganism diversity increases with age, and there are significant 
phylogenetic differences amongst populations living in different countries and regions [69]. Many of 
these differences are due to diet and the availability of particular nutrients in the environment with 
increases in proportions of various bacterial species found to be primarily related to functional 
requirements. For example, individuals living in rural Africa and South America have gut microbiomes 
that are more similar to those of herbivorous animals, whereas Western microbiomes are more 
reflective of those of carnivores [70]. Thus, these are clear adaptations determined in response to 
varying diets in these regions. 
Over the past several years some interesting trends were discovered in regards to functions of gut 
micobiota. Though some studies have shown clear variability in the composition of human microbiota 
over time, the functional potential of the microbiome remains strikingly stable [71]. Using 
metagenomic approaches, it has been shown that 12% of gut-related metabolic pathways are different 
between IBD patients and healthy controls versus only 2% of genus-level clades in this context [72]. In 
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keeping with taxonomic profiling studies revealing lessening numbers of Firmicutes, one metagenomic 
trend that has been shown is that there is a reduction in butyrate and propionate metabolism genes in 
CD [72], as well as lower levels of other SCFAs [43]. There is also an increase in functions associated 
with auxotrophic bacteria, including a decrease in amino acid biosynthesis, and an increase in amino 
acid transfer [72]. Given the presence of tissue destruction in inflammatory conditions, these bacteria 
tend to thrive in such conditions where nutrients are easily accessible in the environment [72]. 
Furthermore, studies have shown an increase in sulphate-reducing bacteria in IBD, an interesting fact 
when one considers that a mechanism of a common medical treatment for IBD, mesalamine, is the 
inhibition of fecal sulphide production [73]. Genes that take part in the metabolism of the  
sulfa-containing amino acid cysteine are increased in IBD, as is increased sulphate transport [72]. 
6. Impact of Cigarette Smoking on the Microbiome 
Other environment factors also impact the gut microbiota. Smoking is an important risk factor in 
IBD pathogenesis with most studies showing a protective effect of cigarette smoking in UC and a 
deleterious effect in CD [74,75]. Smoking cessation induces prominent alterations in the composition 
of normal intestinal flora [76]. After cigarette cessation, comparable shifts have been seen in flora 
composition as have been described in obese versus lean humans and mice [63,77]; specifically, an 
increase in the proportion of Firmicutes relative to Bacterioidetes. Moreover, a concurrent mean 
weight gain of 2.2 kg occurred during the observation period of these mice, in the absence of 
alterations in total calorie intake or other dietary changes [76], suggesting a role of commensal 
organism changes and consequent metabolic alterations in pathogenic weight gain post smoking 
cessation. However, the precise molecular and cell effects of smoking and smoking cessation on gut 
microbiota continue to be relatively poorly understood and are an area for further detailed study. 
7. Impact of Antimicrobial Therapy on the Microbiome 
It is well known that, since the 1950s, antibiotics have been liberally used in the agricultural 
industry as growth promoters, though the mechanism for this effect has been poorly understood. 
Notably, in Canada and the U.S., the heaviest use of such antimicrobials is within farms, with 
restricted doses fed to livestock in order to increase their growth by up to 15% [78,79]. Interestingly, 
these effects have shown to be relatively consistent across a broad variety of vertebrate species, 
including mammals (cattle, swine, sheep) and birds (chickens, turkeys), and follow oral administration 
of these antibiotics, suggesting that the gastrointestinal microbiota may be a notable target [80]. 
Moreover, the fact that these effects are not agent specific and have been shown true for macrolides, 
tetracyclines, pencillins, and other agents, indicates that these growth effects are not side effects associated 
with a particular class of antimicrobials. Within this context, it has been postulated that sub-therapeutic 
administration (STA) of such molecules may modify the structure of the gut microbiome and its 
metabolic function to a significant extent [80]. In fact, we know well that antibiotics can have a great 
effect on the composition of the microbiome in comparison to other environmental factors. As alluded 
to earlier, antibiotics administered within the first year of life are believed to cause atrophy of the 
microbiome and to increase the risk of future autoimmune disease as a consequence [20]. 
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Interestingly, murine model studies have confirmed that STA of antimicrobials can both increase 
adiposity in mice, as well as increase hormone levels that play a role in metabolism by altering the 
proportions of various microbiota. Specifically, one recent novel study showed that an increase in 
relative concentrations of Firmicutes compared to Bacterioidetes in mice treated with STA of 
antibiotics [80]. Perhaps even more interestingly, STA of these molecules were shown in this study to 
stimulate adipogenesis by increasing SCFA levels and, thereby, by providing direct energy to 
colonocytes [80], confirming some of the functional pathway alterations that occur as a result of 
antimicrobial administration. This loss of equilibrium and homeostasis may become substantial when 
prolonged, and may result in changes in host health and subsequent disease [81]. Indeed, murine 
studies are currently being explored to define models for a variety of diseases related to microbiome 
shifts and alterations as a result of antimicrobial use. 
8. Therapeutic Approaches and Applications of the Microbiome 
Though antimicrobials have a well-established role in the treatment of septic complications of IBD, 
their benefit in treating the underlying disease process is more controversial. A number of controlled 
trials and observational studies have been published over the last 30 years regarding the use of 
antibiotics in treating CD [82–84]. Most of these are small studies of short duration and with 
significant methodological disadvantages, including the use of different endpoints and outcomes. 
However, a 2011 meta-analysis of randomized controlled trials revealed superiority of antibiotics to 
placebo in the induction of remission of active CD as well as in the maintenance of remission [85]. 
Another meta-analysis of 10 randomized trials in 2012 demonstrated an improvement in symptoms in 
IBD patients treated with antibiotics as opposed to placebo [86]. Regarding UC, the 2011  
meta-analysis showed a modest benefit in induction of remission of active disease via antibiotics 
relative to placebo [85], though less promising than in CD. In reference to the study by Selby et al., 
though anti-tuberculosis treatment has shown some benefit in CD, it is unclear whether this is as a 
result of the treatment of MAP, the treatment of other commensal organisms or via other nonspecific 
anti-inflammatory effects [55]. In terms of the choice of antimicrobial regimen, though there is 
significant variation and little standardization in the literature, most would advocate for the use of a 
combination of ciprofloxacin and metronidazole based primarily on clinical experience. 
Probiotics are “live micro-organisms which, when administered in adequate amounts, confer a 
health benefit on the host” [87]. Indeed, several studies in mouse models have demonstrated 
prevention of the onset of colitis and reduction of inflammation in established disease using 
Lactobacillus spp. and mixed culture supplementation [88–90]. However, clinical data on the use of 
probiotics in humans is limited and most studies have not been placebo controlled [91]. Moreover, 
more study is needed on the properties of different bacterial strains for various indications, as well as 
information on combinations, dosage and duration of therapy. A related intervention involves the use 
of prebiotics, food ingredients that are not digested or absorbed in the upper GI tract and which are 
fermented in the lower GI tract, promoting the growth of micro-organisms with beneficial effects. For 
instance, inulin and oligofructose are fermented in the large intestine and encourage the growth of 
native lactobacilli and bifidobacteria among other organisms, effects which are associated with 
reduced mucosal inflammation in animal models of IBD [92]. 
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Fecal microbiota transplantation (FMT) is a procedure, which has rapidly grown in acceptability 
and popularity over the past decade. In the animal kingdom, coprophagy (consumption of feces) is 
quite common and observed in a variety of species [93,94]. The practice of transfaunation, the transfer 
of gastrointestinal contents, between animals has been practiced for centuries by veterinarians and, 
whether conducted naturally or artificially, contributes to accelerated maturation of the gut, enhanced 
digestion of nutrients and increased resistance to colonization of the gut by pathogenic organisms [95]. 
Historically, despite an innate repugnance for stool, human civilization has used variations of FMT for 
thousands of years. The earliest known documentation of this comes from Chinese medicine, referring 
to the use of various fecal preparations for the treatment of human gastrointestinal illnesses [96]. 
However, there are also examples of such practice in other parts of the world, including Europe in the 
late 1600s, where Dr. Franz Paullini, a German physician, published a book on the uses of human and 
animal feces entitled Hailsame Dreck-Apotheke (Salutary Filth-Pharmacy) [95]. 
In modern times, FMT has been hailed as an extremely effective therapeutic procedure for 
treatment refractory Clostridium difficile infection (CDI) [97]. At this point in time, the FDA is 
allowing the use of FMT for CDI that remains refractory to other therapeutic modalities. Given the 
success of FMT for this indication, it would be sensible to believe that this procedure or derivatives 
thereof may eventually be applied to several other medical conditions on a more regular basis, 
including IBD. Some researchers now advocate for the streamlining of FMT by such interventions as 
“auto-banking,” in which a sample of patients’ stool is collected and frozen on admission to an 
inpatient facility for later implantation after completion of antimicrobial therapy [98]. Though theoretically 
reasonable, such methods will certainly require further study and approval by regulatory bodies. 
In the context of increasing evidence of the importance of our normal microbiota for the 
maintenance of health and prevention of disease, there has been a recent explosion of interest in 
modulating the microbiome to restore balance and promote health. One such application, a derivative 
of FMT, has been labelled as “Microbial Ecosystem Therapeutics” (MET) and involves the replacement of 
a damaged and/or dysfunctional microbiota with a fully developed and “healthy” constellation of 
intestinal bacteria in a synthetic fashion [99]. As opposed to traditional probiotic therapies, which 
involve the use of a single strain or a few strains of bacteria, MET involves the application of entire 
intestinal bacterial populations, which more closely resemble our own normal flora. The potential 
implications for such therapy are vast and include the treatment of CDI in addition to IBD, irritable 
bowel syndrome (IBS), obesity and metabolic syndrome, and even certain types of autism [99]. 
However, it should be noted that at present the use of FMT or MET for non-CDI indications is an 
area of intense study and that the optimal approaches appear unclear. Despite anecdotal reports of 
successful treatment of UC and CD [100,101], others, including Kump et al., have reported no clinical 
improvement in small series of patients with UC [102]. It is clear that this is a ripe area for further research. 
Moreover, SCFAs, the main metabolic products of anaerobic fermentation in the bowel, have been 
recognized as important mediators in intestinal epithelial barrier permeability and immune function [60]. 
Indeed, higher concentrations of such fatty acids in the intestines and in the blood have a direct impact 
on reduction of predisposition to or intensity of inflammatory conditions, including IBD and cancer [60]. 
In this context, many researchers are now considering the potential therapeutic applications of SCFAs 
and their derivatives in the treatment of IBD [103–105]. Though results have been quite positive 
overall, further study is necessary to establish the dose, frequency and form of SCFA products to 
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receive ideal results. Yet another implication of this research is the use of potential SCFA receptor 
agonists to achieve desired effects in terms of strengthening intestinal barrier permeability and priming 
the immune system. 
Though the use of antimicrobials leading to selection of multi-drug resistant organisms (MDROs) is 
a growing cause for concern, many researchers would now argue that the likelihood of such 
medications to disturb indigenous flora, facilitating the spread of prior selected resistant strains or their 
resistant traits, is even more important [98]. This pressure on the microbiome will, of course, not only 
impact individual patients, but the whole of society as MDROs continue to spread as a result. Several 
important studies have now demonstrated that our current antibiotics, though effective as anti-infective 
agents, can cause significant collateral harm to our microbiome [106,107]. In this context, another 
important application of the microbiome in therapeutics involves studying the impact that each of our 
current antimicrobial classes makes in this realm, and to put stewardship measures in place to favour 
the use of drugs that have a low microbiome damage profile. This approach could be further expanded 
to the preclinical drug approval process to ensure that our drugs in development have the lowest 
possible impact on the status of our normal commensals [107]. Not only will this aid in improving the 
outcomes of individual patients, but will also help with infection control efforts to prevent and/or 
shorten the duration of MDRO colonization. 
Furthermore, other researchers have advocated for the use of specific medications to be given after 
an antimicrobial course is complete in order to break down or bind any residual drug that will only 
serve to further damage the microbiome [108,109]. Indeed, there is a time lag of several weeks to 
months (and sometimes longer) between the final administration of antimicrobials and reconstitution 
of the microbiome to pre-treatment levels. This delay, in animal models, is linked with an increased 
propensity to secondary infections [110]. 
As we look to the future and as more knowledge is gained regarding host-microbiome interactions 
and the biochemical and immunologic interactions that lead to the release of antimicrobial peptides 
and maintenance of barrier immunity, desired effects may be achieved through novel modalities and 
approaches. Perhaps, we may one day manipulate the host into producing the peptides produced by an 
intact and healthy microbiome through the application of bacterial antigens or, better yet, the 
administration of purified peptides and other protective molecules without the need for application of 
live micro-organisms [98]. This will allow healthcare providers to artificially assist with healing the 
host intestinal barrier without subjecting the patient to the fecal transplant-associated risk of pathogen 
transmission and will avoid the inherent aversion to receiving a FMT. 
9. Conclusions 
Environmental factors, including the microbial composition of the gut, may be as important as 
genetic determinants in the pathogenesis of IBD, such as CD and UC. However, many details are yet 
to be determined. Despite this, it is clear that IBD disease pathogenesis involves a combination of an 
aberrant immune system along with dysbiosis in the gut microbiome. Further study and a better 
understanding of important host-microbial interactions will allow us to accelerate our development of 
novel therapeutic applications, such as FMT and MET, the use of innovative scoring systems for the 
impact of antimicrobials on the microbiome, and the hopeful eventual use of purified peptides and 
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other molecules. The ultimate goal will be to optimally restore the normal and healthy mutualistic 
balance between the host and microbiota, which has existed for millennia. 
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